Prostate Neuroendocrine Carcinoma
NCI Definition: A small cell or rarely a large cell neuroendocrine carcinoma that arises from the prostate gland. 
Prostate neuroendocrine carcinomas most frequently harbor alterations in TP53, RB1, TMPRSS2, PTEN, and ERG .
TP53 Mutation, TP53 c.217-c.1178 Missense, TP53 Missense, RB1 Loss, and TP53 Loss are the most common alterations in prostate neuroendocrine carcinoma .
There are 4 clinical trials for prostate neuroendocrine carcinoma, of which 4 are open and 0 are completed or closed. Of the trials that contain prostate neuroendocrine carcinoma as an inclusion criterion, 2 are phase 1 (2 open) and 2 are phase 2 (2 open).
Ipilimumab, nivolumab, and abiraterone are the most common interventions in prostate neuroendocrine carcinoma clinical trials.
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 6. This dataset does not represent the totality of the genetic landscape; see paper for more information.